Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn`s Disease


A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren(TM) (Natalizumab) in Subjects With Moderately to Severely Active Crohn`s Disease With Elevated C-Reactive Protein




The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn`s Disease.

Study Status: Completed


Condition Intervention Phase
Crohn`s Disease Drug: Antegren(TM) (natalizumab) Phase 3

Verified by Elan Pharmaceuticals March, 2012

Sponsored by: Elan Pharmaceuticals
Information provided by: Elan Pharmaceuticals identifier: NCT00078611

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site